Site Search

1. 201.
   OGM for acute leukemia variant detection - Association for Molecular Pathology

   In nearly 20% of cases, additional genetic variants were found that standard ... remarkable utility, refining diagnosis or risk stratification in nearly 20% of cases by identifying critical genetic variants that were otherwise ... and scope in conventional tests. “The finding that nearly 20% of cases within our cohort had a clinically significant abnormality

   https://www.amp.org/about/newsroom/amp-blog-content/ogm-for-acute-leukemia-varia...
2. 202.
   AMP/assets/File/education/case-studies/0720_38-39_AMPcase-LowRes(2)(1).pdf?pass...

   Asp816Val 5.4% DNMT3A c.2648del p.Leu883fs 7.3% TET2 c.5885C>T p.Pro1962Leu 48.5% Table 1. Myeloid malignancy next-generation sequencing results represent a minor criterion for SM diagnosis, information regarding the importance of additional mutations detected in mast cell disease is emerging. Recent retrospective studies evaluating non-KIT mutations by

   https://www.amp.org/AMP/assets/File/education/case-studies/0720_38-39_AMPcase-Lo...
3. 203.
   AMP/assets/File/education/case-studies/0820_46-48_AMPcase_reprint-LowRes.pdf?pass=...

   Tyr646SerMissense mutation24.9%KMT2Dc.4135_4136delATp.Met1379fsFrameshift36.8%ERCC2c.594+2_594+5delTGAGSplice donor variant45.9%Table 1. Mutations identified in the lymphoma sample by NGS mal clinical management remains to be determined.7Our case confirms that BLL-11q usually shows complex karyotypes and has lower levels of MYC expression compared with

   https://www.amp.org/AMP/assets/File/education/case-studies/0820_46-48_AMPcase_re...
4. 204.
   AMP/assets/AMPcommentstoFDA-FDA-2017-N-6356-FINAL.pdf?pass=60

   IVDs performed well exceeding 97% accuracy for the genes BRAF, EGFR, and KRAS combined.2 The authors noted that more than 60% of participants using an FDA-reviewed test adapted the test to accommodate patient ... based on the responses from 383 laboratories --an overall accuracy of 99.4% was obtained.3 These types of findings further support the notion that

   https://www.amp.org/AMP/assets/AMPcommentstoFDA-FDA-2017-N-6356-FINAL.pdf?pass=6...
5. 205.
   Molecular Biomarker Evaluation Colorectal Cancer Guideline Summary of Recommendati...

   It is suggested that a benchmark of 90% of specimens should be sent out within three working days. ... able to detect mutations in specimens with at least 5% mutant allele frequency, taking into account the analytical sensitivity of ... and predictive. Note: It is suggested that a benchmark of 90% of reports available within 10 working days from date of procedure

   https://www.amp.org/AMP/assets/file/clinical-practice/colorectal-cancer-recommen...
6. 206.
   AMP/assets/File/clinical-practice/1023_30-33_AMPcase-Israelyan-reprint_HighRes...

   ClinVar interpretation CDKN2A p.V126D c.377T>A 47% Pathogenic RAD51C p.Q143R c.428A>G 47% Likely pathogenic (1) Uncertain significance (8 ERCC4 p.? c.580_584+1del 48% Likely pathogenic (2) Uncertain significance (1 4|CAP TODAYthan 113,000 women. N Engl J Med. 2021;384(5):428–439. 19. Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of

   https://www.amp.org/AMP/assets/File/clinical-practice/1023_30-33_AMPcase-Israely...
7. 207.
   AMP/assets/File/advocacy/AMP_Comments_on_CMS_Notice_of_Proposed_Rulemaking_3326_9_...

   Regarding Proposed 20% increase in CLIA Administrative Fees In 2019, AMP supported a 20% increase in fees to cover the cost of administering the CLIA program as required by ... been increased. However, we are concerned that CLIA intends to impose an additional 20% increase in fees this year without providing transparency in how the previous increase stabilized

   https://www.amp.org/AMP/assets/File/advocacy/AMP_Comments_on_CMS_Notice_of_Propo...
8. 208.
   AMP/assets/File/annualreports/2019AnnualReport51921.pdf?pass=15

   PhD 900 (35.7%) MD 1104 (43.8%) Other 518 (20.5%) Recipients of the Jeffrey A. Kant Leadership Award gathered at the 2019 Annual Meeting & Expo.2019 AMP Global Organizing Committee in Hong Kong. A S S O C I A T I O N F O R M O L E C U L A R P A T H O L O G Y 10 2 0 1 9 A N N U A L R E P O R T Educating AROUND THE WORLD & ONLINEAMP’s educational

   https://www.amp.org/AMP/assets/File/annualreports/2019AnnualReport51921.pdf?pass...
9. 209.
   Microsoft Word - 060612_Abstract Submission Record Breaking.doc

   Receives 40% Increase in Abstract Submissions Bethesda, MD, June 13, 2012: the Association for Molecular Pathology (AMP) announced a recordbreaking number of abstract submissions for the AMP 2012 Annual Meeting on Genomic Medicine, marking a 40% increase over last year. The Meeting will be held October 25-27, 2012 in Long Beach, CA. An increase in the

   https://www.amp.org/AMP/assets/File/pressreleases/2012/6-13-12-AbstractSubmissio...
10. 210.
    The COVID-19 testing conundrum: What consumers should know about the...

    If someone actually has the virus infecting them, these tests find it 80-90% of the time and are almost never “positive” when no virus is present. As new variants emerge ... have told the FDA, these tests usually will fail to detect the virus in more than 15% of individuals who, in fact, have a positive RT-PCR test. These “rapid antigen” tests are more

    https://www.amp.org/about/newsroom/amp-blog-content/the-covid-19-testing-conundr...